DMC and Conagen enter into an agreement for commercial manufacturing of L-alanine


Type of post: NEWS IN BRIEF.

DMC Biotechnologies and Conagen have entered into a manufacturing agreement for the commercial production of DMC’s first product, L-alanine.
Related posts:

Figure 1. L-alanine

This partnership combines Conagen’s production expertise with DMC’s bioprocess technology and follows demonstration of commercial-scale production in March 2021. L-alanine is a naturally occurring amino acid used widely in homecare products, human nutrition, and pharmaceutical applications. DMC’s fermentation technology enables L-alanine to be produced with attractive economics as part of a regional supply chain with increased reliability and greater sustainability. DMC has a robust product pipeline, including additional amino acids, that will subsequently be brought to the market.

Popular Posts

UPM Lappeenranta Biorefinery

Mitsui Chemicals, Neste and Toyota Tsusho join forces for industrial production of biobased plastics and chemicals

Nextchem awarded an engineering contract for the sustainable aviation fuel plant of TotalEnergies in Grandpuits

Eni is investigating the opportunity to build a new biorefinery in Livorno

Biobased adipic acid